ACELRX PHARMACEUTICALS INC's ticker is ACRX and the CUSIP is 00444T100. A total of 85 filers reported holding ACELRX PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $7,000 | -12.5% | 34,182 | 0.0% | 0.00% | – |
Q2 2022 | $8,000 | -20.0% | 34,182 | 0.0% | 0.00% | – |
Q1 2022 | $10,000 | -47.4% | 34,182 | 0.0% | 0.00% | – |
Q4 2021 | $19,000 | -45.7% | 34,182 | 0.0% | 0.00% | – |
Q3 2021 | $35,000 | -25.5% | 34,182 | 0.0% | 0.00% | – |
Q2 2021 | $47,000 | -87.7% | 34,182 | -84.8% | 0.00% | – |
Q1 2021 | $382,000 | +30.4% | 224,939 | -4.8% | 0.00% | – |
Q4 2020 | $293,000 | -15.3% | 236,256 | -2.9% | 0.00% | – |
Q3 2020 | $346,000 | +15.7% | 243,420 | -1.5% | 0.00% | – |
Q2 2020 | $299,000 | +9.1% | 247,090 | +6.2% | 0.00% | – |
Q1 2020 | $274,000 | -46.9% | 232,586 | -4.8% | 0.00% | – |
Q4 2019 | $516,000 | -4.1% | 244,346 | 0.0% | 0.00% | – |
Q3 2019 | $538,000 | -16.3% | 244,346 | -3.8% | 0.00% | – |
Q2 2019 | $643,000 | +195.0% | 253,974 | +306.1% | 0.00% | – |
Q1 2019 | $218,000 | +40.6% | 62,542 | -6.9% | 0.00% | – |
Q4 2018 | $155,000 | -7.2% | 67,149 | +55.1% | 0.00% | – |
Q3 2018 | $167,000 | +12.1% | 43,283 | -1.6% | 0.00% | – |
Q2 2018 | $149,000 | +22.1% | 44,003 | -24.5% | 0.00% | – |
Q1 2018 | $122,000 | +10.9% | 58,263 | +7.2% | 0.00% | – |
Q4 2017 | $110,000 | -64.9% | 54,329 | -20.1% | 0.00% | – |
Q3 2017 | $313,000 | +114.4% | 67,961 | 0.0% | 0.00% | – |
Q2 2017 | $146,000 | -58.9% | 67,961 | -39.7% | 0.00% | – |
Q1 2017 | $355,000 | +29.1% | 112,682 | +6.6% | 0.00% | – |
Q4 2016 | $275,000 | -43.5% | 105,740 | -15.5% | 0.00% | – |
Q3 2016 | $487,000 | +24.6% | 125,162 | -14.0% | 0.00% | – |
Q2 2016 | $391,000 | +111.4% | 145,477 | +142.4% | 0.00% | – |
Q1 2016 | $185,000 | +25.0% | 60,018 | +56.3% | 0.00% | – |
Q4 2015 | $148,000 | +26.5% | 38,402 | 0.0% | 0.00% | – |
Q3 2015 | $117,000 | -28.2% | 38,402 | 0.0% | 0.00% | – |
Q2 2015 | $163,000 | -72.7% | 38,402 | -75.1% | 0.00% | – |
Q1 2015 | $596,000 | -46.3% | 154,388 | -6.4% | 0.00% | – |
Q4 2014 | $1,110,000 | +27.1% | 164,892 | +3.7% | 0.00% | – |
Q3 2014 | $873,000 | -69.5% | 158,991 | -43.1% | 0.00% | – |
Q2 2014 | $2,866,000 | +72.2% | 279,582 | +101.8% | 0.00% | – |
Q1 2014 | $1,664,000 | +13.2% | 138,576 | +6.6% | 0.00% | – |
Q4 2013 | $1,470,000 | -58.8% | 129,955 | -60.7% | 0.00% | -100.0% |
Q3 2013 | $3,568,000 | +153.8% | 330,966 | +118.2% | 0.00% | – |
Q2 2013 | $1,406,000 | – | 151,706 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 6,574,060 | $25,376,000 | 1.97% |
SENZAR ASSET MANAGEMENT, LLC | 1,040,681 | $4,017,000 | 0.98% |
Cormorant Asset Management, LP | 850,000 | $3,281,000 | 0.51% |
Palo Alto Investors LP | 2,135,739 | $8,244,000 | 0.41% |
Opus Point Partners Management, LLC | 99,959 | $386,000 | 0.32% |
Granahan Investment Management | 1,527,837 | $5,897,000 | 0.17% |
WALL STREET ASSOCIATES | 367,200 | $1,417,000 | 0.13% |
CAXTON CORP | 21,870 | $84,000 | 0.10% |
SHEPHERD KAPLAN KROCHUK, LLC | 107,392 | $415,000 | 0.07% |
Joel Isaacson & Co., LLC | 70,660 | $273,000 | 0.07% |